文献速递姑息放疗与转移瘤中枢神经肿瘤放疗

体能状态与合并症对姑息性放疗耐受性及终末期决策的影响

Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making.
PubMed 文献 · Adv Radiat Oncol · 2018-09-14

本研究纳入2016年1月1日至6月30日期间接受脑或骨姑息性放疗的145例患者,分析Karnofsky体能状态(KPS)与合并症对姑息性放疗耐受性和分割方案的影响。结果显示高合并症(P=0.029)及中等(P=0.051)、差(P=0.065)体能状态与更频繁的主要治疗中断相关,但高合并症和低KPS并未与更短的治疗计划相关,距死亡时间更短的患者也未更可能接受短程分割(P=0.871)。

要点

  • 高合并症(P=0.029)与中等(P=0.051)、差(P=0.065)体能状态与更频繁的主要治疗中断相关。
  • 高合并症和低KPS评分与更短的治疗计划无关联。
  • 距死亡时间更早的患者并未更可能接受短程分割(P=0.871)。

核心结论

  • 低KPS和高合并症评分预示更差的预后和更频繁的主要治疗中断,但无迹象表明医生在分割方案安排中纳入了这些信息。

研究设计与样本

  • 研究纳入2016年1月1日至2016年6月30日期间接受脑或骨姑息性放疗的患者,共145例,其中骨转移95例、脑转移50例。
  • 收集人口学与医学特征包括KPS评分(良好90-100、中等70-80、差≤60)、社会经济状态、合并症(采用Adult Comorbidity Evaluation-27量表的二分类测量)、转移部位和治疗机构。
  • 采用Cox比例风险回归模型进行单变量分析,评估各变量对处方分割数(二分类:≥10为长程分割方案,<10为短程分割方案)和主要治疗中断(定义为缺失≥3个放疗治疗日或提前结束治疗)的影响。

主要发现

  • 高合并症(P=0.029)以及中等(P=0.051)和差(P=0.065)功能状态与更频繁的主要治疗中断相关。
  • 高合并症和低KPS评分与更短的治疗计划无关联。
  • 距死亡时间更早的患者并未更可能接受短程分割(P=0.871)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. METHODS AND MATERIALS: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). RESULTS: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P = .029) and both fair (P = .051) and poor (P = .065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P = .871). CONCLUSIONS: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Perlow HK, Cassidy V, Farnia B, et al. Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making. Adv Radiat Oncol. 2018. PMID: 30706020. doi:10.1016/j.adro.2018.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。